Company: imec
LinkedIn Post Text: hashtag#WorldCancerDayResearchers from imec and KU Leuven achieved the first clinical validation of imec’s cell sorter chip technology. The cell sorter was used to detect a specific kind of immune cell. It accurately identified PD-1 positive T-cells, matching the precision of established cytometry standards. This advancement may facilitate creating a point-of-care tool for immune profiling, a crucial aspect of personalized cancer therapy. Current tools for immune profiling, like flow cytometry, are limited to use in centralized labs due to their bulkiness, cost, and complexity. Imec’s cell sorter technology could lead to a portable alternative, that would enable oncologists to assess immune conditions in an office or daycare setting using a drop of blood. Such a portable system would facilitate repeated immune profiling, enabling more effective and tailored cancer treatments. hashtag#CloseTheCareGap https://ow.ly/NVu250QxfUE
…see more
Media Link: https://ow.ly
You’re reading a preview. Unlock the full article by upgrading →